Im­muno­core un­veils ear­ly-stage da­ta of skin can­cer treat­ment that led it to start Phase 3 tri­al

CHICA­GO — Im­muno­core re­port­ed Fri­day that in an ear­ly-stage study, 56% of melanoma pa­tients who re­ceived its ex­per­i­men­tal drug achieved dis­ease con­trol — a mea­sure­ment that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER